AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05016115 — intervention group
Intervention type: BEHAVIORAL
Intervention: survey
Description: The Turkish reworded student version of the Jefferson scale of physician empathy was used. Empathy scores were compared related to study years and gender.
Study NCT03263962 — intervention group
Intervention type: DRUG
Intervention: Canrenone
Description: Evaluation of canrenone therapy in patients with CHF
Study NCT04220541 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor learning based exercise
Description: Symptomatic exercise
Study NCT00874510 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mandatory Naps
Description: As above, interns on extended duty overnight call shifts will be required to transfer cell phones and cross-coverage responsibilities to night float residents for a 5 hour period each night they are on call. For Year 2, interns will nap in shifts, instead of concurrently, with the first nap shift between 12am-3am and the second shift between 3am-6am
Study NCT03658265 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 7 days SIE plus 4 weeks PRE
Description: Shoulder isotonic exercise (SIE)：exercise methods for shortening and relaxing the muscles around the shoulder joint.~Progressive resistance exercise (PRE)：A training method that gradually increases the resistance, which will increase the muscle capacity.
Study NCT03658265 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 7 days SIE plus 3 weeks PRE
Description: Shoulder isotonic exercise (SIE)：exercise methods for shortening and relaxing the muscles around the shoulder joint.~Progressive resistance exercise (PRE)：A training method that gradually increases the resistance, which will increase the muscle capacity.
Study NCT03658265 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3 days SIE plus 4 weeks PRE
Description: Shoulder isotonic exercise (SIE)：exercise methods for shortening and relaxing the muscles around the shoulder joint.~Progressive resistance exercise (PRE)：A training method that gradually increases the resistance, which will increase the muscle capacity.
Study NCT03658265 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3 days SIE plus 3 weeks PRE
Description: Shoulder isotonic exercise (SIE)：exercise methods for shortening and relaxing the muscles around the shoulder joint.~Progressive resistance exercise (PRE)：A training method that gradually increases the resistance, which will increase the muscle capacity.
Study NCT01391286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost solution 0.03%
Description: One drop of bimatoprost solution 0.03% applied along each upper eyelid margin once daily in the evening for 4 months.
Study NCT01391286 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bimatoprost vehicle solution
Description: One drop of bimatoprost vehicle solution applied along each upper eyelid margin once daily in the evening for 4 months.
Study NCT04049838 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: postoperative analgesia for lower abdominal surgery in children
Description: compare lateral and posterior approaches of trannsversus abdominis plane block for analgesia after lower abdominal surgery in children
Study NCT00939783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon
Description: Tablet for oral administration
Study NCT00964535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide and formoterol 200/6 microg
Description: 2 inhalations as a single dose
Study NCT00964535 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonide and formoterol 200/6 microg
Description: 2 inhalations as a single dose
Study NCT00964535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide and formoterol 200/6 microg
Description: 2 inhalations as a single dose with the concurrent charcoal blockage
Study NCT00964535 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonide and formoterol 200/6 microg
Description: 2 inhalations as a single dose with the concurrent charcoal blockage
Study NCT00409084 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic variceal band ligation
Description: endoscopic variceal band ligation
Study NCT01783275 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: 12 weeks of aerobic exercise with weight maintenance
Study NCT03672409 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Intervention in knowledge
Description: The knowledge intervention will be done through four group learning sessions with the objective of significantly increasing diabetes knowledge in health professionals.~The learning sessions will be carried out weekly in a period of 4 weeks, with a duration of 60 minutes per session. In addition, two sessions will be held for the evaluation of pre and post intervention knowledge. The learning sessions consist in the diagnosis, evaluation, complications and comorbidities, pharmacological treatment and nutrition in type 2 diabetes.
Study NCT01298752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mapracorat
Description: Mapracorat ophthalmic suspension 3%, one drop in post-operative study eye once daily (QD) for 2 weeks.
Study NCT01298752 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle of mapracorat ophthalmic suspension, one drop in post-operative study eye once daily (QD) for 2 weeks.
Study NCT01664559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Ketorolac 30mg intramuscular injection, 1cc volume
Study NCT01664559 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Placebo arm, 1cc of normal saline, 0.9%, intramuscular injection
Study NCT02895880 — intervention group
Intervention type: BEHAVIORAL
Intervention: usual care
Description: In order to characterize the content of and variation in usual care, the first 25 patients enrolled in the study will complete a post-visit questionnaire that asks what their doctor told them (if anything) about their risk of cardiovascular disease, risk reduction and statins specifically, and how this information was presented
Study NCT02895880 — intervention group
Intervention type: BEHAVIORAL
Intervention: statin communication tool
Description: The Statin Choice decision aid uses icon arrays to communicate the expected benefits of statins. This modified risk communication tool will maintain the components of the validated original. The adapted paper-based risk communication tool will describe modified risk profiles applicable to the survivors at increased risk for cardiac disease due to chest irradiation.
Study NCT03741114 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Foley's Catheter
Description: patients managed by Intrauterine Inflated Foley's Catheter Balloon after delivery of the fetus.
Study NCT03741114 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TA
Description: patients received 1 gm tranexamic acid intravenous just before skin incision in 100 ml saline
Study NCT03741114 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: patients received 100 ml saline just before skin incision
Study NCT00868062 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Succinylated gelatine, 40g/L, (Gelofusine - B Braun)
Description: 1 litre infusion following induction of anaesthesia
Study NCT03113656 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weighted Blanket
Description: Weighted blanket placed on infant for 30 minutes
Study NCT03113656 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-Weighted Blanket
Description: Non-Weighted blanket placed on infant for 30 minutes
Study NCT01833286 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE+RFA
Description: TACE first, followed by RFA within 2 months
Study NCT01833286 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: re-resection
Description: repeat hepatectomy for recurrent small HCC
Study NCT04722575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib 20 MG Oral Tablet
Description: Cobimetinib 60 mg qd p.o. from week 1 to week 3 and week 5 to week 6. Week 4 off.
Study NCT04722575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib 240 Mg Oral Capsule
Description: 960 (arm A) /720 (arm B) mg bid p.o. from week 1 to week 6.
Study NCT04722575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 MG in 20 ML Injection
Description: 840 mg IV for 2 cycles for Arm B and C. After surgery in all arms 1200 mg IV for 52 weeks
Study NCT04227262 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MIRROR THERAPY
Description: The children were instructed to sitting on chair and a mirror is placed in midsagittal plane of the child, with the normal limb in front of mirror and the affected limb is blocked so the patient see only the reflected movement of the sound limb (non affected).
Study NCT01353820 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 1- Low fat drinkable fermented by Lactobacillus Delbruckii lactis (DN111244) - >10E8 <5.10E9 cfu/mL
Description: 1- Intervention with test product ( >10E8 to \<5.10E9 cfu/ml of L. delbruckii lactis )
Study NCT01353820 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: 2- Low fat drinkable fermented by S. thermophilus and L. bulgaricus
Description: 2- Intervention with control product
Study NCT01053390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatostatin
Description: Somatostatin 3mg+NS（normal saline）60ml, a continuous intravenous infusion, q12h
Study NCT01053390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin, cisplatin, LV（Leucovorin）、 5-FU（5-Fluorouracil）
Study NCT01053390 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epirubicin, cisplatin, LV（Leucovorin）、 5-FU（5-Fluorouracil）
Study NCT04474756 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: custom-made adjustable mandibular advancement device
Description: a custom-made mandibular repositioning device (MRD), available under medical prescription for the treatment of adult obstructive sleep apnea (OSA) and snoring. It maintains the mandible in an advanced position along the occlusal plane. This ensures patient comfort and treatment efficacy.
Study NCT04474756 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: custom-made adjustable mandibular advancement device
Description: a custom-made mandibular repositioning device (MRD), available under medical prescription for the treatment of adult obstructive sleep apnea (OSA) and snoring. It maintains the mandible in an advanced position along the occlusal plane. This ensures patient comfort and treatment efficacy.
Study NCT03879733 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Thrive by Three
Description: The intervention consists of the following components:~1. Measurement of daycare quality with CLASS (Classroom Assessment Scoring System) 3 times during the intervention period~2. Feedback to group staff on 8 CLASS-quality dimensions~3. Monthly supervision of staff on two levels: supervision of daycare staff, and supervision of supervisors~4. Competence building with all staff: 3 full training days, plus 2 extra training days for pedagogical leaders/supervisors~5. Written material to parents, supervisors, and staff~6. Web page for staff and parents: tf3.no
Study NCT03879733 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as usual (TAU)
Description: The wait-list control group will continue with their daily activities and work in the childcare as usual. The wait list control group will have received general information about the study prior to consenting, however no materials or are provided by project. The child-care centers in the control conditions will receive a gift certificate of 3000 Norwegian Crones (NOK) by the end of the intervention period.
Study NCT04247061 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational video
Description: One of two different 10 minute educational videos on smoking cessation will be viewed by participants during a dental cleaning visit. The video that is watched will depend on participants' level of motivation to quit and project needs
Study NCT04247061 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text-message program
Description: A one-month text message program to motivate and facilitate contact with smoking cessation resources.
Study NCT04496401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus and Tacrolimus Extended Release Oral Tablet [Envarsus]
Description: Phase 1: standard dose and frequency tacrolimus, used in accordance with licensing and local protocols. Suitable target trough level should be between 7-14 ng/ml.~Phase 2: ENVARSUS® (LCP Tacro - extended release tacrolimus), used once-daily at an initial dose of 0.17mg/kg, dose adjusted to maintain an appropriate therapeutic blood concentration (measured by trough level). Suitable target trough level should be between 7-14 ng/ml.
Study NCT01303042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin lispro mix 50/50
Description: Insulin lispro mix 50/50 t.i.d : six months
Study NCT02512224 — intervention group
Intervention type: DEVICE
Intervention: Parenteral nutrition
Description: Participants are retrospectively selected with propensity score matching
Study NCT02512224 — intervention group
Intervention type: DEVICE
Intervention: Enteral nutrition
Description: Participants are retrospectively selected with propensity score matching
Study NCT04173676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green for Injection
Description: The sentinel lymph nodes were observed by submucosal injection of ICG
Study NCT00263029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 60mg/m² as a 2-hour intravenous infusion every week for 5-6 week
Study NCT00263029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 500mg tablets and 150mg tablets. 750mg/m² bd given approximately 12 hours apart
Study NCT00263029 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Planned total dose of 45-50.4Gy (with cone down) in 25-28 fractions
Study NCT00730964 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Perflutren Protein-Type A Microspheres Injectable Suspension, United States Pharmacopeia (USP)
Description: The recommended dose of Optison is 0.5mL injected into a peripheral vein. This may be repeated for further contrast enhancement as needed.~The injection rate should not exceed 1mL per second. Follow the Optison injection with a flush of 0.9% sodium chloride injection, USP or 5% dextrose in water injection, United States Pharmacopeia (USP) .~The maximum total dose should not exceed 5.0mL in any 10 minutes period. The maximum total dose should not exceed 8.7mL in any one patient study.
Study NCT01925690 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing-Cognitive Behavioral Therapy
Description: A telephone based talk therapy discussing pros and cons of medication use in MS.
Study NCT01925690 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Education
Description: Give patients a pamphlet discussing pros and cons of disease modifying therapies
Study NCT01925690 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Education
Description: Give patients a pamphlet discussing pros and cons of disease modifying therapies
Study NCT02079857 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard protocol
Description: Subjects will receive a standard treatment
Study NCT02079857 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized protocol
Description: Subjects will receive an individualized treatment
Study NCT02079857 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture/Placebo moxa
Description: Subjects will receive sham acupuncture/placebo moxa
Study NCT02943564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapastinel
Description: Rapastinel pre-filled syringes for weekly IV injections.
Study NCT02943564 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-matching rapastinel pre-filled syringes for weekly IV injections.
Study NCT03385603 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dilator
Description: Both groups will have a home program consisting of dilators which are progressive in size. The standard care group will use manufacturer instructions to progress in size of dilators, while the experimental group will use self-reported levels of fear to progress in size of dilators.
Study NCT03385603 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dilator
Description: Both groups will have a home program consisting of dilators which are progressive in size. The standard care group will use manufacturer instructions to progress in size of dilators, while the experimental group will use self-reported levels of fear to progress in size of dilators.
Study NCT03385603 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fear-Based Questionnaires
Description: Series of questionnaires used to facilitate emotional awareness associated with vaginal and decreased sexual arousal.
Study NCT02461550 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Irreversible Electroporation Ablation
Study NCT04066036 — intervention group
Intervention type: OTHER
Intervention: This is an observational study only.
Description: This is an observational study only.
Study NCT01567657 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pethidin hydrochlorid, midazolam
Description: Pethidin hydrochlorid: 25 mg iv. at the beginning of the examination Midazolam: 1-2 mg iv. at the beginning of the examination. Repetitive given in a dosis of 1 mg iv. until a total amount of 7 mg iv.
Study NCT01567657 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: 50 years and over: initial dose of 50-60 mg Propofol iv. Followed by bolus of 20-30 mg iv. until sedation is achieved.~\< 50 years: initial dose 30-40 mg Propofol iv. Followed by bolus of 10-20 mg until sedation is achieved.
Study NCT04721470 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined therapy
Description: Patients undergoing combined therapy
Study NCT04721470 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microwave ablation
Description: Patients undergoing Microwave ablation
Study NCT04721470 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transarterial chemoembolization
Description: Patients undergoing Transarterial chemoembolization
Study NCT04662658 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Hyperpolarized Xenon -129 MRI
Description: e-cigarette sub-study
Study NCT01252745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10.0 mg of Testosterone, 4.0% TID
Study NCT01252745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 13.5 mg of Testosterone, 4.5% B.I.D
Study NCT01252745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11.25 mg of Testosterone, 4.5% T.I.D
Study NCT03163589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Description: injection
Study NCT03163589 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: injection
Study NCT03491007 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DHEA
Description: Subjects will be randomized to receive a one-time oral dose of DHEA (400mg) or PBO and sustained administration of the study drug for 6 weeks. There will be a 2 week placebo lead-in period \[all participants\], followed by subjects continuing in the randomization block of DHEA or placebo for 6 weeks following acute administration).
Study NCT02625233 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon C
Study NCT02625233 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comfilcon A
Study NCT01833442 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Kundalini Yoga Meditation
Description: The trial will compare two very different meditation protocols. After the 4.5 month the patients will be reevaluated, and all patients will be merged together into a single group. Patients will then receive 9 - 12 more months of the meditation protocol.
Study NCT01833442 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Response Meditation
Description: The trial will compare two very different meditation protocols. After the 4.5 month the patients will be reevaluated, and all patients will be merged together into a single group. Patients will then receive 9 - 12 more months of the meditation protocol.
Study NCT02802748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Vinorelbine
Description: Metronomic Schedule of Vinorelbine administered orally in a schedule monday-wednesday-friday, tuesday-thursday-saturday, etc
Study NCT02802748 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Vinorelbine
Description: Metronomic Schedule of Vinorelbine administered orally in a schedule monday-wednesday-friday, tuesday-thursday-saturday, etc
Study NCT02802748 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Letrozole will be administered orally at 2.5 mg QD for 3 weeks.
Study NCT02802748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole will be administered orally at 2.5 mg QD for 3 weeks.